ANI Pharmaceuticals Inc (ANIP)
Liquidity ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 3.57 | 3.70 | 3.74 | 2.90 | 3.46 | 3.79 | 3.35 | 3.79 | 3.68 | 2.25 | 2.14 | 2.21 | 2.17 | 2.18 | 1.98 | 2.00 | 3.04 | 1.07 | 1.01 | 0.92 |
| Quick ratio | 2.63 | 2.77 | 2.72 | 1.93 | 2.15 | 2.41 | 2.22 | 2.62 | 2.61 | 1.44 | 1.31 | 1.41 | 1.32 | 1.34 | 1.28 | 1.30 | 2.18 | 0.76 | 0.70 | 0.64 |
| Cash ratio | 1.52 | 1.44 | 1.32 | 0.54 | 0.49 | 0.69 | 0.66 | 0.97 | 1.15 | 0.18 | 0.27 | 0.30 | 0.10 | 0.24 | 0.35 | 0.26 | 1.01 | 0.35 | 0.24 | 0.23 |
ANI Pharmaceuticals Inc has exhibited strong liquidity levels over the past eight quarters based on its current ratio, quick ratio, and cash ratio. The current ratio has consistently remained above 3, indicating that the company has more than enough current assets to cover its current liabilities. This suggests that ANI Pharmaceuticals Inc has a strong ability to meet its short-term obligations.
The quick ratio, which excludes inventory from current assets, also reflects a healthy liquidity position for the company. The consistent values above 2 signify that ANI Pharmaceuticals Inc can cover its short-term liabilities without relying on the sale of inventory.
Moreover, the cash ratio, which is the most stringent measure of liquidity, has shown a positive trend for ANI Pharmaceuticals Inc. The values have generally remained above 1, indicating the company's ability to cover its current liabilities solely with cash and cash equivalents.
Overall, based on the liquidity ratios, ANI Pharmaceuticals Inc appears to have a robust liquidity position, which may provide the company with flexibility in managing its short-term financial obligations and pursuing growth opportunities.
Additional liquidity measure
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash conversion cycle | days | 197.70 | 227.00 | 250.32 | 272.08 | 297.03 | 289.59 | 321.56 | 317.00 | 337.57 | 314.15 | 336.36 | 360.24 | 379.17 | 364.87 | 322.72 | 357.85 | 321.41 | 315.93 | 325.42 | 289.83 |
The cash conversion cycle of ANI Pharmaceuticals Inc has shown fluctuations over the past eight quarters. The company's cash conversion cycle measures the time it takes for the company to convert its investments in inventory and accounts receivable into cash from sales.
In Q4 2023, the cash conversion cycle was 271.36 days, showing an improvement compared to the previous quarter (Q3 2023) where it was 306.23 days. This suggests that the company was able to manage its inventory and accounts receivable more efficiently in the most recent quarter.
Looking back over the past eight quarters, ANI Pharmaceuticals Inc has experienced variations in its cash conversion cycle, with the cycle peaking at 406.58 days in Q1 2022. The downward trend since then indicates that the company has been more effective in managing its working capital and converting it into cash.
Overall, a decreasing trend in the cash conversion cycle indicates that the company is becoming more efficient in managing its working capital, which could potentially lead to improved cash flow and financial performance. ANI Pharmaceuticals Inc should continue to monitor and optimize its cash conversion cycle to ensure effective working capital management.